Drugs /

autologous gamma-retroviral msgv1 139 scfv egfrviii car gene-modified t cells

Back to Drugs List

Overview

NCI Definition [1]:
A preparation of autologous T-lymphocytes transduced with the gamma retroviral vector MSGV1 expressing a chimeric T-cell antigen receptor (CAR) consisting of a single-chain variable fragment (scFv) from a specific antibody clone (mAb139) that targets a mutant form of epidermal growth factor receptor (EGFR) known as variant III (EGFRvIII; EGFR-vIII), with potential antineoplastic activity. Upon intratumoral administration, the gamma-retroviral MSGV1 139 scFv EGFRvIII CAR gene-modified T-cells specifically target and bind to tumor cells expressing EGFRvIII, leading to selective cytotoxicity in EGFRvIII-expressing tumor cells. EGFRvIII, a tumor-associated antigen (TAA) encoded by an in-frame deletion of exons 2-7 in the EGFR gene, is specifically overexpressed by a subset of tumor cells and is not expressed in normal, healthy cells. It plays a key role in tumor cell proliferation, tumor angiogenesis and radio- and chemoresistance.

Clinical Trials

View Clinical Trials for autologous gamma-retroviral msgv1 139 scfv egfrviii car gene-modified t cells

Autologous gamma-retroviral msgv1 139 scfv egfrviii car gene-modified t cells has been investigated in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial investigating autologous gamma-retroviral msgv1 139 scfv egfrviii car gene-modified t cells, 1 is phase 1 (0 open).

EGFR Exons 2-7 Skipping is the most frequent biomarker inclusion criterion for autologous gamma-retroviral msgv1 139 scfv egfrviii car gene-modified t cells clinical trials.

Glioblastoma and gliosarcoma are the most common diseases being investigated in autologous gamma-retroviral msgv1 139 scfv egfrviii car gene-modified t cells clinical trials [2].

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Autologous Gamma-Retroviral Msgv1 139 Scfv Egfrviii Car Gene-Modified T Cells
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating autologous gamma-retroviral msgv1 139 scfv egfrviii car gene-modified t cells and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
msgv1-egfrviii-specific car-transduced autologous t lymphocytes, msgv1-egfrviii-car autologous t cells, gamma-retroviral msgv1 139 scfv egfrviii car gene-modified autologous t-lymphocytes, autologous gamma-retroviral msgv1 139 scfv egfrviii car gene-modified t cells
Drug Target(s) [2]:
EGFR
NCIT ID [1]:
C143060

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.